Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy

• Shu-Fu Lin ,

  * E-mail: wongr@mskcc.org (RJW); mmg@cgmh.org.tw (SL)

  Affiliation Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, Republic of China

  ⨯
• Yu-Yao Huang,

  Affiliation Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, Republic of China

  ⨯
• Jen-Der Lin,

  Affiliation Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, Republic of China

  ⨯
• Ting-Chao Chou,

  Affiliation Laboratory of Preclinical Pharmacology Core, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Chuen Hsueh,

  Affiliation Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, Republic of China

  ⨯
• Richard J. Wong

  * E-mail: wongr@mskcc.org (RJW); mmg@cgmh.org.tw (SL)

  Affiliation Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯